The human trial of COVID-19 vaccine candidate developed by the University of Oxford and backed by AstraZeneca Plc has shown a positive result. The researchers found their experimental COVID-19 vaccine produced a dual immune response in people aged 18 to 55. Oxford’s vaccine is designed to reduce disease and transmission. Director at the Jenner Institute of Oxford University, Dr Adrian Hill, explains the mechanism of this vaccine “this vaccine triggers both arms of the immune system”.
As per the British Medical Journal Lancet:
The vaccine was officially known as AZD1222, prompted a protective immune response in hundreds of people who got the shot and did not prompt any serious side effects. According to trial results published in The Lancet medical journal, the Covid-19 vaccine prompted no serious side effects and elicited antibody and T-cell immune responses with the strongest response seen in people who received two doses.
About AZD1222 vaccine:
India, a land of diverse cultures, landscapes, and histories, continues to enchant travelers from around…
The world of Yakshagana, a traditional theatre form of Karnataka, has lost a towering figure.…
Japan, often referred to as the "Land of the Rising Sun," is a captivating island…
IndusInd Bank, in collaboration with Circularity Innovation Hub India Private Limited (CIH), has achieved a…
The Reserve Bank of India (RBI) has instructed Talkcharge Technologies to halt the issuance and…
In the latest advancement of China's space program, the Shenzhou-18 mission saw the successful launch…